Carcinogenesis Advance Access originally published online on November 18, 2004
Carcinogenesis 2005 26(3):643-647; doi:10.1093/carcin/bgh342
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis vol.26 no.3 © Oxford University Press 2004; all rights reserved.
ARTICLE |
The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk
1 Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, Germany, 2 Department of Biosciences at Novum, Karolinska Institute, Huddinge, Sweden, 3 Institute of Transfusion Medicine and Immunology, Red Cross Blood Service of Baden-Württemberg-Hessia, Faculty of Clinical Medicine, University of Heidelberg, Mannheim, Germany, 4 Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany and 5 Division of Molecular Gynaeco-Oncology, Department of Gynaecology and Obstetrics, Clinical Center, University of Cologne, Cologne, Germany
* To whom correspondence should be addressed. Tel: +49 6221 421802; Fax: +49 6221 421810; Email: b.frank{at}dkfz.de
Overexpression of the proto-oncogene ERBB2 (HER2/NEU) has been observed in 20–30% of breast cancers involving poor prognosis. Genetic alterations within ERBB2 have been shown to induce carcinogenesis and metastasis. We investigated eight annotated single nucleotide polymorphisms for occurrence in familial breast cancer samples. The confirmed variants Ile654Val, Ile655Val and Ala1170Pro were analysed in subsequent epidemiological studies on familial breast cancer risk. While Ala1170Pro resides within a C-terminally located regulatory domain, the two adjacent polymorphisms Ile654Val and Ile655Val are part of the transmembrane domain. A case–control study analysing a cohort of 348 German familial breast cancer cases and 960 corresponding controls showed no significant association of either Ile655Val (OR = 1.05, 95% CI = 0.82–1.34, P = 0.728) or Ala1170Pro (OR = 0.94, 95% CI = 0.74–1.20, P = 0.632) with familial breast cancer risk. Differences in haplotype frequencies between cases and controls could also not be detected. The ERBB2 variant Ile654Val, however, revealed an increased risk for carriers of the heterozygous Val654 allele (OR = 2.56, 95% CI = 1.08–6.08, P = 0.028). The rare Val654 variant is linked with the more frequent Val655, resulting in two consecutive valine instead of two isoleucine residues within the transmembrane domain. Computational analyses suggest that the Val654–Val655 allele provokes receptor dimerization and activation, thus stimulating kinase activity and cell transformation. We hypothesize that ERBB2 Val654 represents an oncogenic variant which might, in addition, influence clinical outcome and predict a worse prognosis.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Frank, M. Wiestler, S. Kropp, K. Hemminki, A. B. Spurdle, C. Sutter, B. Wappenschmidt, X. Chen, J. Beesley, J. L. Hopper, et al. Association of a Common AKAP9 Variant With Breast Cancer Risk: A Collaborative Analysis J Natl Cancer Inst, March 19, 2008; 100(6): 437 - 442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Beauclair, P Formento, J. Fischel, W Lescaut, R Largillier, E Chamorey, P Hofman, J. Ferrero, G Pages, and G Milano Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity Ann. Onc., August 1, 2007; 18(8): 1335 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Frank, J. L. Bermejo, K. Hemminki, C. Sutter, B. Wappenschmidt, A. Meindl, M. Kiechle-Bahat, P. Bugert, R. K. Schmutzler, C. R. Bartram, et al. Copy number variant in the candidate tumor suppressor gene MTUS1 and familial breast cancer risk Carcinogenesis, July 1, 2007; 28(7): 1442 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Frank, K. S. Shanmugam, L. Beckmann, K. Hemminki, H. Brenner, M. Hoffmeister, J. Chang-Claude, and B. Burwinkel Death receptor 4 variants and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 2002 - 2005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Frank, K. Hemminki, B. Wappenschmidt, A. Meindl, R. Klaes, R. K. Schmutzler, P. Bugert, M. Untch, C. R. Bartram, and B. Burwinkel Association of the CASP10 V410I variant with reduced familial breast cancer risk and interaction with the CASP8 D302H variant Carcinogenesis, March 1, 2006; 27(3): 606 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Frank, K. Hemminki, K. S. Shanmugam, A. Meindl, R. Klaes, R. K. Schmutzler, B. Wappenschmidt, M. Untch, P. Bugert, C. R. Bartram, et al. Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk Carcinogenesis, November 1, 2005; 26(11): 1975 - 1977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Frank, K. Hemminki, and B. Burwinkel A bias in genotyping the ERBB2 (HER2) Ile655Val variant Carcinogenesis, September 1, 2005; 26(9): 1649 - 1649. [Full Text] [PDF]
|
|
|
|
 |
|
 S. De Brakeleer, E. Teugels, J. De Greve, B. Frank, R. Klaes, B. Burwinkel, G. A. Calin, C. M. Croce, and D. Neuberg Familial Cancer and ARLTS1 N. Engl. J. Med., July 21, 2005; 353(3): 313 - 314. [Full Text] [PDF]
|
|
|
|
|
|
B. Frank, J. L. Bermejo, K. Hemminki, R. Klaes, P. Bugert, B. Wappenschmidt, R. K. Schmutzler, and B. Burwinkel Re: Association of a Common Variant of the CASP8 Gene With Reduced Risk of Breast Cancer J Natl Cancer Inst, July 6, 2005; 97(13): 1012 - 1012. [Full Text] [PDF]
|
|